Literature DB >> 17572015

Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo.

Sachiko Ogasawara1, Hirohisa Yano, Seiya Momosaki, Jun Akiba, Naoyo Nishida, Sakiko Kojiro, Fukuko Moriya, Hironori Ishizaki, Keitaro Kuratomi, Masamichi Kojiro.   

Abstract

We investigated the effects of interferon-beta (IFN-beta) on the growth of human liver cancer cells. The effects of IFN-beta with or without 5-fluorouracil (5-FU) on the proliferation of 13 liver cancer cell lines were investigated in vitro. Chronologic change in IFN-alpha receptor 2 (IFNAR-2) expression was monitored in hepatocellular carcinoma (HCC) cells (HAK-1B) cultured with IFN-beta. After HAK-1B cells were transplanted into nude mice, various doses of IFN-beta were administered, and the tumor volume, weight, histology, tumor blood vessel, and angiogenesis factor expression were examined. IFN-beta inhibited the growth of 11 cell lines with apoptosis in a dose-dependent and time-dependent manner. With IFN-beta, IFNAR-2 expression in HAK-1B cells was significantly downregulated from 6 to 12 h. IFN-beta induced a dose-dependent decrease in tumor volume and weight and a significant increase of apoptosis in the tumor. Both basic fibroblast growth factor (bFGF) and blood vessel number in the tumor decreased only in mice receiving the lowest dose (1000 IU) of IFN-beta. IFN-beta with 10 muM of 5-FU frequently induced synergistic antiproliferative effects. IFN-beta with or without 5-FU induces strong antitumor effects in HCC cells, and we conclude that IFN-beta is useful for the prevention and treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17572015     DOI: 10.1089/jir.2007.0183

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  10 in total

1.  Antiproliferative effect of ME3738, a derivative of soyasapogenol, on hepatocellular carcinoma cell lines in vitro and in vivo.

Authors:  Sachiko Ogasawara; Jun Akiba; Masamichi Nakayama; Hironori Kusano; Hirohisa Yano
Journal:  Biomed Rep       Date:  2016-10-25

2.  Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Hiroaki Hagihara; Kazuhiro Nouso; Yoshiyuki Kobayashi; Yoshiaki Iwasaki; Shinichiro Nakamura; Kenji Kuwaki; Junichi Toshimori; Hirokazu Miyatake; Hideki Ohnishi; Hidenori Shiraha; Kazuhide Yamamoto
Journal:  Int J Clin Oncol       Date:  2010-12-09       Impact factor: 3.402

3.  1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis.

Authors:  Miroslaw Kornek; Veronika Lukacs-Kornek; Andreas Limmer; Esther Raskopf; Ursula Becker; Maren Klöckner; Tilman Sauerbruch; Volker Schmitz
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

4.  Cross-priming for antitumor CTL induced by soluble Ag + polyI:C depends on the TICAM-1 pathway in mouse CD11c(+)/CD8α(+) dendritic cells.

Authors:  Masahiro Azuma; Takashi Ebihara; Hiroyuki Oshiumi; Misako Matsumoto; Tsukasa Seya
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

5.  Co-regulatory expression quantitative trait loci mapping: method and application to endometrial cancer.

Authors:  Kenneth S Kompass; John S Witte
Journal:  BMC Med Genomics       Date:  2011-01-12       Impact factor: 3.063

6.  Sensitization of glycoengineered interferon-β1a-resistant cancer cells by cFLIP inhibition for enhanced anti-cancer therapy.

Authors:  Tae-Eun Kim; Sungyoul Hong; Kyoung Song; Sang-Ho Park; Young Kee Shin
Journal:  Oncotarget       Date:  2017-02-21

7.  Oncogenic Mutation BRAF V600E Changes Phenotypic Behavior of THLE-2 Liver Cells through Alteration of Gene Expression.

Authors:  Magdalena Śmiech; Paweł Leszczyński; Christopher Wardell; Piotr Poznański; Mariusz Pierzchała; Hiroaki Taniguchi
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

8.  Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways.

Authors:  Puja Kumari; Irene Saha; Athira Narayanan; Sathish Narayanan; Akinori Takaoka; Nachimuthu Senthil Kumar; Prafullakumar Tailor; Himanshu Kumar
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

9.  Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation.

Authors:  Elisabeth Müller; Martin Speth; Panagiotis F Christopoulos; Anna Lunde; Ajna Avdagic; Inger Øynebråten; Alexandre Corthay
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

10.  Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.

Authors:  Amber Blaauboer; Stephanie Booy; Peter M van Koetsveld; Bas Karels; Fadime Dogan; Suzanne van Zwienen; Casper H J van Eijck; Leo J Hofland
Journal:  BMC Cancer       Date:  2020-09-23       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.